Information Provided By: 
Fly News Breaks for September 10, 2019
IMMU
Sep 10, 2019 | 11:17 EDT
Jefferies analyst Chris Howerton says that Immunomedics competitor DS-1062 showed "impressive" efficacy of 70%-plus cORR at RP2D, but he notes that n=7 is "quite small," and baseline characteristics could be different. Importantly, the analyst points out that one patient died of respiratory failure, and four reported potential ILD since data cutoff, including one death. Overall, he does not view DS-1062 as near-term comparable to IMMU-132's current pipeline. Howerton reiterates a Buy rating and $22 price target on Immunomedics' shares.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
